Modality
Bispecific Ab
MOA
AuroraAi
Target
JAK2
Pathway
DDR
PVRBObesity
Development Pipeline
Preclinical
~Jun 2012
→ ~Sep 2013
Phase 1
~Dec 2013
→ ~Mar 2015
Phase 2
~Jun 2015
→ ~Sep 2016
Phase 3
~Dec 2016
→ ~Mar 2018
NDA/BLA
~Jun 2018
→ ~Sep 2019
Approved
Dec 2019
→ Sep 2031
ApprovedCurrent
NCT06636735
18 pts·PV
2019-12→2030-06·Not yet recruiting
NCT03336604
2,076 pts·Obesity
2025-08→2031-09·Completed
NCT05403578
788 pts·Obesity
2023-05→TBD·Not yet recruiting
+1 more trial
4,326 total pts2 indications
CompletedCurrentUpcoming
Catalysts (3)
2030-06-254.2y awayPh3 Readout· PV
2031-02-204.9y awayPh3 Readout· Obesity
2031-09-065.4y awayPh3 Readout· Obesity
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
Approved
Not yet…
Approved
Not yet…
Approved
Termina…
Approved
Complet…
Catalysts
Ph3 Readout
2030-06-25 · 4.2y away
PV
Ph3 Readout
2031-02-20 · 4.9y away
Obesity
Ph3 Readout
2031-09-06 · 5.4y away
Obesity
CompletedTerminatedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06636735 | Approved | PV | Not yet recr... | 18 | FEV1 |
| NCT03336604 | Approved | Obesity | Completed | 2076 | BodyWt |
| NCT05403578 | Approved | Obesity | Not yet recr... | 788 | Safety |
| NCT06079333 | Approved | Obesity | Terminated | 1444 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| Semasacituzumab | Jazz Pharma | Phase 2 | AHR | |
| Teravorutinib | Illumina | Phase 2 | JAK2 | |
| ILM-2412 | Illumina | Phase 3 | PLK4 |